Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 17, 2007

Bayer Schering Taps VTT to Study Cancer Drug

  • VTT and Bayer Schering Pharma will collaborate to study the mode of action of a Bayer’s new cancer drug. As part of this two-year research contract, VTT will use its new gene and cell biology methods.

    VTT’s focus is on identifying primary driver genes and targets of genetic alterations in cancer. The company also works toward finding drug compounds preventing the growth and metastasis of breast and prostate cancer.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »